Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs, Inc. filings document the regulatory record for an NYSE-listed digital manufacturing company that produces custom parts for prototyping, testing, bridge production, short-run production, and end-use applications. Its SEC disclosures cover operating results, revenue by service activity, non-GAAP measures, cash-flow commentary, and business updates related to CNC machining, digital platforms, and manufacturing capacity.
PRLB filings also include Form 8-K material-event reports for earnings releases and executive leadership changes, amendments to previously furnished results information, and proxy materials covering board matters, executive compensation, equity awards, shareholder voting items, and governance. The company’s filings identify its common stock under the PRLB ticker on the New York Stock Exchange.
Proto Labs, Inc. filed an amended current report to correct a guidance figure in its previously issued outlook. The amendment clarifies that the company’s GAAP diluted earnings per share guidance range for the first quarter of 2026 is $0.18 to $0.26, instead of the $0.17 to $0.25 range originally described in the attached press release. No other aspects of the earlier report or the press release were changed, and the correction is described as a scrivener’s error.
Proto Labs, Inc. reported record fourth-quarter 2025 revenue of $136.5 million, up 12.1% from a year ago, and returned to profitability with net income of $6.0 million, or $0.25 per diluted share, versus a small loss last year. Non-GAAP net income was $10.7 million, or $0.44 per diluted share.
For full year 2025, revenue reached a record $533.1 million, a 6.4% increase, with net income rising to $21.2 million, or $0.88 per diluted share. CNC Machining led growth, while 3D Printing and Injection Molding declined slightly. Adjusted EBITDA was $78.1 million, a 14.7% margin, and operating cash flow was $74.5 million, supporting a year-end cash and investments balance of $142.4 million.
Management highlighted four strategic pillars—elevating customer experience, accelerating innovation, expanding production, and driving operational efficiency—and issued 2026 guidance calling for 6% to 8% revenue growth. For Q1 2026, the company expects revenue of $130.0 million to $138.0 million and diluted EPS of $0.17 to $0.25, or $0.36 to $0.44 on a non-GAAP basis.
Proto Labs, Inc. Chief Operations Officer Michael R. Kenison reported the acquisition of 8,128 shares of Proto Labs common stock on January 29, 2026, at a reported price of $0 per share. Following this transaction, he beneficially owns 37,026 shares of Proto Labs common stock in direct ownership, as disclosed in this Form 4 insider filing.
Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported acquiring additional company stock. On January 29, 2026, he acquired 20,686 shares of Proto Labs common stock at a reported price of $0 per share. Following this transaction, he directly beneficially owned 47,645 shares of Proto Labs common stock, as disclosed in this Form 4 insider filing.
An affiliated holder of PRLB has filed a notice of proposed sale of restricted or control securities under Rule 144. The person plans to sell 368 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of 01/16/2026 on the NYSE. These 368 common shares were acquired on 05/15/2025 through an Employee Stock Purchase Plan from the issuer and paid for in cash.
Over the prior three months, the same seller, Oleg Ryaboy, has reported multiple sales of the issuer’s common stock, including 9,710 shares sold on 11/07/2025 for gross proceeds of 471,629.27 and 7,178 shares sold on 01/15/2026 for gross proceeds of 393,330.00. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Proto Labs (symbol PRLB) received a Rule 144 notice from shareholder Oleg Ryaboy covering planned sales of common stock. The notice states an intention to sell 7,178 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $393,329.99, at a time when 23,678,745 common shares were outstanding.
The shares to be sold come from option exercises under a registered plan on 01/15/2026, where 3,048 and 4,130 common shares were acquired for cash on that same date. The filing also lists prior sales by the same shareholder over the past three months: 695, 9,710, 7,026, and 6,669 common shares, with gross proceeds of $34,686.76, $471,629.27, $384,413.54, and $357,327.02, respectively.
Form 144 discloses that Oleg Ryaboy plans to sell 7,026 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/08/2026, with an indicated aggregate market value of 384,413.54. The stock is listed on the NYSE, and the issuer has 23,678,745 shares of this class outstanding.
The shares to be sold were acquired on 01/08/2026 by exercising options under a registered plan, in two transactions of 1,164 and 5,862 shares paid in cash. The notice also reports that during the past three months, Oleg Ryaboy sold additional common shares in three transactions, including 9,710 shares for gross proceeds of 471,629.27 on 11/07/2025 and 6,669 shares for 357,327.02 on 01/07/2026. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
PRLB has a shareholder filing a notice to sell common stock under Rule 144. The filing covers a proposed sale of 6,669 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $357,327.02. The shares were acquired on 01/07/2026 by exercising options under a registered plan and were paid for in cash the same day.
The notice also lists recent sales in the past three months for the same seller, including 9,710 common shares sold on 11/07/2025 for gross proceeds of $471,629.27 and 695 common shares sold on 11/25/2025 for $34,686.76. By signing, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s operations.
Proto Labs Inc. Chief Operations Officer reported an amended insider transaction involving company common stock. On November 25, 2025, the officer exercised 3,048 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares. That same day, the officer sold 3,048 common shares at a weighted average price of $50.1741 per share under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025. After these transactions, the officer beneficially owned 28,898 common shares directly. The filing also clarifies that the stock options were fully vested and corrects the stated expiration date of the options to February 14, 2026, fixing a clerical error in a prior report while leaving all other transaction details unchanged.
Proto Labs, Inc. (PRLB) reported an insider transaction by its Chief Operations Officer on a Form 4. On 11/25/2025, the officer exercised an employee stock option for 3,048 shares of common stock at an exercise price of $33.84 per share, then sold 3,048 shares of common stock in open-market transactions at a weighted average price of $50.1741 per share. After these transactions, the officer directly beneficially owned 28,898 shares of Proto Labs common stock and held 4,664 employee stock options following the reported exercise. The filing notes that the trades were made under a Rule 10b5-1 trading plan adopted on August 15, 2025, and that the ownership total includes 57 shares acquired through the company’s employee stock purchase plan.